Vanderbilt-Ingram Cancer Center

Vanderbilt-Ingram website >

March 28, 2024

Study identifies molecule as potential target for treating AML

While immune checkpoint inhibitors that target the PD-1 molecule on T-cells have proven to be effective with many cancers, these immunotherapies have not worked for acute myeloid leukemia (AML), but new research has identified a “cousin” molecule as a potential therapeutic target for AML. 

By Tom Wilemon
March 8, 2024

Scalp cooling allows woman to keep hair during chemotherapy

The Food and Drug Administration first granted marketing approval for the DigniCap system for patients with breast cancer in 2015, then in 2017 the FDA expanded the authorization, making it the first cooling cap cleared for use in cancer patients with solid tumors, such as breast cancer, ovarian cancer and colorectal cancer.

By Tom Wilemon
March 5, 2024

GE HealthCare & Vanderbilt publish data on AI models predicting patient response to immunotherapy

The results from a research partnership between GE HealthCare and Vanderbilt University Medical Center utilizing artificial intelligence to enable safer and more precise cancer immunotherapies show that the models they developed predict patient responses with 70% to 80% accuracy.

By Tom Wilemon
January 22, 2024

Molecular profiles of tissue plus circulating tumor DNA can better guide cancer care

Vanderbilt research indicates that adding liquid biopsy testing for circulating tumor DNA mutations increases targetable mutation detection rates.

By Tom Wilemon
January 9, 2024

Chic Awearness supports mentoring program for ovarian cancer patients

Chic Awearness is now supporting two new ovarian cancer research initiatives at Vanderbilt University Medical Center and providing matching funding for a social worker to coordinate Woman to Woman, a peer mentoring program launched at VUMC in 2023.

By Tom Wilemon
January 5, 2024

Artificial intelligence advances work in VUMC’s clinical and research settings

Vanderbilt University Medical Center physicians and researchers are applying artificial intelligence in innovative ways to advance clinical care and scientific understanding of these cutting-edge tools.

By VUMC News and Communications
January 4, 2024

VUMC in the news, Jan. 9, 2024

January 4, 2024

Potential AML therapy induces leukemic stem cell death

Vanderbilt researchers are studying a potential therapy for acute myeloid leukemia that targets the residual leukemic stem cells in bone marrow after treatment that are responsible for relapses and drug resistance.
By Tom Wilemon
December 20, 2023

Appointments, additions in 2023 strengthen VUMC’s core missions

During the past year, multiple new appointments and additions strengthened VUMC’s core missions.
By VUMC News and Communications
December 15, 2023

Clinical trial shows efficacy for atezolizumab combined with carboplatin

By Tom Wilemon
December 14, 2023

Sam S. Chang recognized by the American Urological Association

The American Urological Association has announced that Vanderbilt's Sam S. Chang, MD, MBA, is one of its 2024 award recipients.
By Tom Wilemon
November 30, 2023

Ukrainian oncologists visit Vanderbilt-Ingram Cancer Center

A group of Ukrainian oncologists recently visited Vanderbilt-Ingram Cancer Center where they toured research labs, observed tumor board meetings, met with several Vanderbilt oncologists, and attended the 23rd Annual Retreat for Cancer Biology.
By Tom Wilemon
November 17, 2023

Keith Obstein receives inaugural Brock Family Center Innovator of the Year Award

Keith Obstein, MD, MPH, has received the inaugural Innovator of the Year Award from the Brock Family Center for Applied Innovation in recognition of his achievements in developing and commercializing a magnetic, flexible colonoscopy system with the potential to provide a safer alternative to standard colonoscopy.
By Jill Clendening
1 … 3 4 5 6 7 … 25